Evidence map›Paper›PMID 36015010›Full record

ReviewPathogens (Basel, Switzerland)2022

Application of CRISPR-Cas9 Gene Editing for HIV Host Factor Discovery and Validation.

William J Cisneros, Daphne Cornish, Judd F Hultquist

Open access · goldAbstract readReview
In one paragraph

Review in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Towards the elimination of infectious HPV: exploiting CRISPR/Cas innovations.Frontiers in cellular and infection microbiology · 2025
    Review
  7. Host Factor Rab4b PromotesMicroorganisms · 2024
    Article
  8. A CRISPR-Cas Cure for HIV/AIDS.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

William J CisnerosDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.ORCID 0000-0003-2472-6167
Daphne CornishDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.ORCID 0000-0003-3835-5694
Judd F HultquistDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.ORCID 0000-0001-6424-4280
Northwestern University · US

Funding

X-ray Screening and Rapid Structure DeterminationP50GM082250 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KROGAN, NEVAN J · 2007 to 2018
$48.8M
Virology and Immunology Technology CoreP30AI117943 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Sahera Dirajlal-Fargo · 2015 to 2026
$38.4M
Project 3U54AI170792 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JENNIFER A DOUDNA · 2022 to 2026
$35.7M
X-ray Screening and Rapid Structure DeterminationP50AI150476 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EMERMAN, MICHAEL · 2019 to 2021
$14.4M
Functionally Defining HIV-Host Interactions During the Early HIV-1 LifecycleR01AI150998 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BIENIASZ, PAUL D., HOPE, THOMAS · 2020 to 2024
$6.8M
Regulation of SAMHD1 antiviral activityR01AI150455 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI DIAZ-GRIFFERO, FELIPE · 2019 to 2024
$3.3M
Deciphering the Role of CPSF6 in HIV InfectionR01AI165236 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HULTQUIST, JUDD F · 2021 to 2025
$2.0M
NIAID NIH HHS P30 AI117943NIAID NIH HHS P50 AI150476NIAID NIH HHS R01 AI150455NIAID NIH HHS R01 AI150998NIAID NIH HHS R01 AI165236NIAID NIH HHS U54 AI170792NIGMS NIH HHS P50 GM082250NIH HHS R01 AI150998
6 · The paper itself

Abstract

Human Immunodeficiency Virus (HIV) interacts with a wide array of host factors at each stage of its lifecycle to facilitate replication and circumvent the immune response. Identification and characterization of these host factors is critical for elucidating the mechanism of viral replication and for developing next-generation HIV-1 therapeutic and curative strategies. Recent advances in CRISPR-Cas9-based genome engineering approaches have provided researchers with an assortment of new, valuable tools for host factor discovery and interrogation. Genome-wide screening in a variety of in vitro cell models has helped define the critical host factors that play a role in various cellular and biological contexts. Targeted manipulation of specific host factors by CRISPR-Cas9-mediated gene knock-out, overexpression, and/or directed repair have furthermore allowed for target validation in primary cell models and mechanistic inquiry through hypothesis-based testing. In this review, we summarize several CRISPR-based screening strategies for the identification of HIV-1 host factors and highlight how CRISPR-Cas9 approaches have been used to elucidate the molecular mechanisms of viral replication and host response. Finally, we examine promising new technologies in the CRISPR field and how these may be applied to address critical questions in HIV-1 biology going forward.

Indexed as

CRISPR-Cas9gene editingHIVhost factorsscreening

Identifiers

PMID36015010
PMCPMC9415735
OpenAlexW4293779364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.